In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials.

We discuss:

Reverse cholesterol transport [1:40];
Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00];
Remnant lipoproteins and apoC-III [16:45];
Particles having sex: lipid exchange [28:00];
Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45];
2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45];
2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15];
2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and
More.

Learn more at www.PeterAttiaMD.com

Connect with Peter on Facebook | Twitter | Instagram.

#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

The Peter Attia Drive

#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins